Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14556020 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL14106729 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL21539004 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL22697521 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24825613 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL10038938 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24824212 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24824209 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL20713594 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL18158169 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | DOUBLERAINBOW BIOSCIENCES INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | DOUBLERAINBOW BIOSCIENCES INC. | 2023-04-20 | — | — | US | disclosed |
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | L3MBTL1 3775/4885LGALS1 2960/4885LGALS3 2007/4885 |
| US-11787834-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | L3MBTL1 3775/4885LGALS1 2960/4885LGALS3 2007/4885 |
| US-20230124589-A1 | Ivacaftor Glycosides, Methods Of Making, And Uses Thereof In Treating Cystic Fibrosis | UGGT1, UGDH, GALE | L3MBTL1 1359/4885LGALS1 402/4885LGALS3 383/4885 |
| US-11325937-B2 | Glycoside compound and preparation method therefor, composition, application, and intermediate | VEGFA, FLT4, FLT1 | L3MBTL1 4302/4885LGALS1 846/4885LGALS3 509/4885 |
| US-20230193336-A1 | ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTION | UGDH, IDH1, G6PD | L3MBTL1 1574/4885LGALS1 435/4885LGALS3 493/4885 |
| US-20230192748-A1 | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug | GALE, UGGT1, DERA | L3MBTL1 1063/4885LGALS1 396/4885LGALS3 346/4885 |
| US-20210115082-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | VEGFA, FLT4, FLT1 | L3MBTL1 4302/4885LGALS1 846/4885LGALS3 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.